Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Inventory (2016 - 2025)

Standard Biotools (LAB) has disclosed Inventory for 16 consecutive years, with $20.0 million as the latest value for Q4 2025.

  • Quarterly Inventory fell 3.68% to $20.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.0 million through Dec 2025, down 3.68% year-over-year, with the annual reading at $20.0 million for FY2025, 3.68% down from the prior year.
  • Inventory for Q4 2025 was $20.0 million at Standard Biotools, down from $25.4 million in the prior quarter.
  • The five-year high for Inventory was $42.6 million in Q3 2024, with the low at $20.0 million in Q4 2025.
  • Average Inventory over 5 years is $26.7 million, with a median of $23.0 million recorded in 2022.
  • The sharpest move saw Inventory soared 93.02% in 2024, then plummeted 43.29% in 2025.
  • Over 5 years, Inventory stood at $20.8 million in 2021, then rose by 3.11% to $21.5 million in 2022, then decreased by 3.39% to $20.7 million in 2023, then changed by 0.0% to $20.7 million in 2024, then dropped by 3.68% to $20.0 million in 2025.
  • According to Business Quant data, Inventory over the past three periods came in at $20.0 million, $25.4 million, and $24.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.